Stockreport

Nuvalent aiming for approval on pivotal trial data for NSCLC candidate [Yahoo! Finance]

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF In the Phase I/II ALKOVE-1 study (NCT05384626), neladalkib was associated with a 31% overall response rate (ORR) amongst patients who had previously received prior trea [Read more]